Regencell Begin Period Cash Flow from 2010 to 2024
| RGC Stock | USD 5.49 0.04 0.73% |
Begin Period Cash Flow | First Reported 2002-06-30 | Previous Quarter 25.4 K | Current Value 1.6 M | Quarterly Volatility 24.7 B |
Check Regencell Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regencell Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 708.3 K, Interest Expense of 19.8 K or Selling General Administrative of 3.5 M, as well as many indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or Days Sales Outstanding of 12.61. Regencell financial statements analysis is a perfect complement when working with Regencell Bioscience Valuation or Volatility modules.
Regencell | Begin Period Cash Flow |
Latest Regencell Bioscience's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Regencell Bioscience Holdings over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Regencell Bioscience's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regencell Bioscience's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Regencell Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 102,567,423 | |
| Geometric Mean | 11,731,448 | |
| Coefficient Of Variation | 108.63 | |
| Mean Deviation | 98,963,738 | |
| Median | 68,000,000 | |
| Standard Deviation | 111,422,217 | |
| Sample Variance | 12414.9T | |
| Range | 279.9M | |
| R-Value | (0.67) | |
| Mean Square Error | 7283.4T | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | (16,810,292) | |
| Total Sum of Squares | 173808.7T |
Regencell Begin Period Cash Flow History
About Regencell Bioscience Financial Statements
Regencell Bioscience stakeholders use historical fundamental indicators, such as Regencell Bioscience's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Regencell Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Regencell Bioscience's assets and liabilities are reflected in the revenues and expenses on Regencell Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Regencell Bioscience Holdings. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 1.6 M | 1.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out the analysis of Regencell Bioscience Correlation against competitors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.